Parkinsonism
A patient has symmetrical Parkinsonism after starting metoclopramide. Explain the possible mechanism:
Metoclopramide blocks D2 receptors → reduces dopaminergic signalling in basal ganglia circuits → parkinsonism develops.
Symmetry and temporal relationship to dopamine-blocking medication make idiopathic PD less likely.
Why does Levodopa work better with carbidopa, even though carbidopa blocks the enzyme needed to make dopamine?
Carbidopa blocks peripheral DOPA decarboxylase but does not cross the BBB → peripheral levodopa is not converted to dopamine → more levodopa reaches brain → central DOPA decarboxylase still converts levodopa to dopamine.
PD usually presents in later adulthood: what is the typical average/median age of diagnosis, and how common is it by age 65?
Average/median diagnosis is around the mid-to-late 50s, about 55–60 years → prevalence rises with age → about 1% of people over 65 have Parkinson’s disease.
Why are soluble α-synuclein oligomers considered more dangerous than mature Lewy bodies?
Soluble oligomers are more biologically active and diffusible → disrupt mitochondria, synapses, membranes, axonal transport, and protein handling → mature Lewy bodies may partly isolate/sequester these toxic species.
A patient has axial rigidity, early falls, poor levodopa response, and impaired downward gaze. What is the likely diagnosis and molecular pathology?
Progressive supranuclear palsy → atypical parkinsonian tauopathy → brainstem involvement produces vertical gaze palsy and early postural instability.
A patient eats a high-protein meal and notices reduced levodopa benefit. Explain the mechanism.
Levodopa uses amino acid transporters in the small intestine and across the BBB → dietary amino acids compete for transport → less levodopa absorbed/transported → reduced CNS dopamine effect.
A patient has resting tremor, rigidity, and bradykinesia. Which feature is most diagnostically essential and why?
Bradykinesia → reflects failure of movement initiation and decrement due to basal ganglia dysfunction → PD diagnosis requires bradykinesia plus rest tremor or rigidity.
Why can α-synuclein pathology produce constipation and REM sleep behaviour disorder before substantia nigra symptoms?
Early α-synuclein deposition can involve enteric/autonomic and lower brainstem circuits before major nigrostriatal dopamine loss → non-motor prodrome precedes bradykinesia.
Parkinsonism with early severe orthostatic hypotension, urinary dysfunction, and cerebellar signs points to which disorder and why?
Multiple system atrophy → α-synucleinopathy with glial cytoplasmic inclusions → affects autonomic, striatonigral, and olivopontocerebellar systems → autonomic failure + Parkinsonism + cerebellar signs.
A patient’s symptoms return predictably before the next levodopa dose. Explain the pharmacokinetic and disease-progression mechanism.
Wearing-off → levodopa has a short half-life and late PD has fewer dopaminergic neurons to buffer dopamine → motor function becomes dependent on plasma levodopa levels → symptoms return as levels fall.
Why does Parkinson’s disease produce both motor and non-motor symptoms rather than only basal ganglia motor signs?
PD is a multisystem α-synucleinopathy → pathology affects central, autonomic, enteric, brainstem, limbic, and cortical systems → motor signs coexist with constipation, orthostatic hypotension, anosmia, REM sleep behaviour disorder, depression, hallucinations, and cognitive decline.
What would you expect to see in surviving substantia nigra neurons in Parkinson’s disease + describe microscopically?
Lewy bodies → eosinophilic intracytoplasmic inclusions with a dense core and pale halo → mainly α-synuclein plus ubiquitin.
Compare idiopathic PD and MSA using protein, cell type, and clinical pattern.
Idiopathic PD → α-synuclein in neurons → Lewy bodies in surviving neurons → asymmetric bradykinesia, rigidity, resting tremor, usually levodopa responsive.
MSA → α-synuclein in oligodendrocytes → glial cytoplasmic inclusions → autonomic failure, cerebellar/pyramidal signs, parkinsonism, poor levodopa response.
A patient develops dyskinesia 30–60 minutes after levodopa and freezing before the next dose. Explain both mechanisms and management logic.
30–60 min post-dose dyskinesia → peak-dose dopamine excess → reduce individual levodopa dose or smooth delivery.
Pre-dose freezing/worsening → wearing-off dopamine deficiency → increase dose frequency or add COMT/MAO-B inhibitor.
A patient has constipation, anosmia, dream enactment, then years later asymmetric bradykinesia — what does this sequence tell you about PD pathology/origin?
α-synuclein pathology likely began outside the nigrostriatal motor system, affecting enteric/autonomic, olfactory, and brainstem circuits before substantia nigra dopamine loss reached the motor threshold.
A Parkinsonian syndrome shows α-synuclein inclusions mainly in oligodendrocytes rather than neurons. Is this idiopathic PD?
No. Oligodendroglial α-synuclein inclusions suggest multiple system atrophy → PD has neuronal Lewy bodies, whereas MSA has glial cytoplasmic inclusions.
Q: A patient is wheelchair-dependent within 5 years of symptom onset, has early falls, poor levodopa response, and lower-limb predominant Parkinsonism.
Explain why this is not typical idiopathic PD and name 3 other possible alternatives.
Idiopathic PD usually progresses more slowly and typically responds to levodopa early.
Rapid progression, early falls, poor levodopa response, and lower-body predominance are red flags → consider PSP, MSA, vascular pseudoparkinsonism, drug-induced parkinsonism, or other atypical/secondary parkinsonian syndromes.
A younger patient is started on a dopamine agonist to delay levodopa complications. List possible side effects + explain possible mechanism
Dopamine agonists directly stimulate dopamine receptors, especially D2-like receptors → also stimulate mesolimbic reward pathways → impulse control disorders such as gambling/hypersexuality, and central sleep-regulation pathways → sudden sleep attacks.
A patient with long-standing Parkinson’s develops hallucinations. Give two competing mechanisms and how timing/context helps separate them.
Medication-related dopamine excess → hallucinations after dopaminergic dose escalation or with dyskinesia/confusion.
Disease progression/Lewy body spread → hallucinations with cognitive fluctuation, dementia, and cortical involvement.
What are the failed protein clearance pathways in PD, and explain the mechanism leading to dopaminergic neuronal death
1. ubiquitin-proteasome and autophagy-lysosomal pathways
2. Failed UPS/autophagy → misfolded α-synuclein is not cleared → oligomers accumulate → mitochondrial dysfunction + oxidative stress → microglial activation → inflammatory cytokines and ROS → progressive dopaminergic neuron injury and death.